EA006445B9 - Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции - Google Patents

Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции

Info

Publication number
EA006445B9
EA006445B9 EA200400183A EA200400183A EA006445B9 EA 006445 B9 EA006445 B9 EA 006445B9 EA 200400183 A EA200400183 A EA 200400183A EA 200400183 A EA200400183 A EA 200400183A EA 006445 B9 EA006445 B9 EA 006445B9
Authority
EA
Eurasian Patent Office
Prior art keywords
ylidene
carboxamide
diethylamino
pyrrole
oxo
Prior art date
Application number
EA200400183A
Other languages
English (en)
Other versions
EA006445B1 (ru
EA200400183A1 (ru
Inventor
Майкл ХОЛИ
Томас Дж. Флек
Стивен П. Прескотт
Марк Т. Малоуни
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA006445(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200400183A1 publication Critical patent/EA200400183A1/ru
Publication of EA006445B1 publication Critical patent/EA006445B1/ru
Publication of EA006445B9 publication Critical patent/EA006445B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Согласно настоящему изобретению предложены кристаллы и их композиции, причем данные кристаллы включают соль яблочной кислоты N-[2-(диэтиламино)этил]-5-[(5-фторо-1,2-дигидро-2-оксо-3H-индол-3-илиден)метил]-2,4-диметил-1Н-пиррол-3-карбоксамида. Кроме того, описаны способы получения таких кристаллов.
EA200400183A 2001-08-15 2002-08-13 Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции EA006445B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (3)

Publication Number Publication Date
EA200400183A1 EA200400183A1 (ru) 2004-08-26
EA006445B1 EA006445B1 (ru) 2005-12-29
EA006445B9 true EA006445B9 (ru) 2017-02-28

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400183A EA006445B9 (ru) 2001-08-15 2002-08-13 Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции

Country Status (43)

Country Link
US (2) US20030069298A1 (ru)
EP (3) EP2332934B1 (ru)
JP (1) JP4159988B2 (ru)
KR (1) KR100639281B1 (ru)
CN (2) CN100439360C (ru)
AP (1) AP1660A (ru)
AR (1) AR036261A1 (ru)
AU (1) AU2002324684B2 (ru)
BG (1) BG108553A (ru)
BR (1) BR0211612A (ru)
CA (1) CA2455050C (ru)
CO (1) CO5550431A2 (ru)
CU (1) CU23713B7 (ru)
CY (1) CY1121552T1 (ru)
CZ (1) CZ2004196A3 (ru)
DK (2) DK1419151T3 (ru)
EA (1) EA006445B9 (ru)
EC (1) ECSP044975A (ru)
ES (3) ES2623094T3 (ru)
GE (1) GEP20063777B (ru)
HK (2) HK1066542A1 (ru)
HR (1) HRP20040112B1 (ru)
HU (1) HU229206B1 (ru)
IL (1) IL160097A0 (ru)
IS (1) IS7147A (ru)
MA (1) MA27058A1 (ru)
ME (1) ME00414B (ru)
MX (1) MXPA04001452A (ru)
MY (1) MY139383A (ru)
NO (1) NO326508B1 (ru)
NZ (1) NZ531232A (ru)
OA (1) OA12650A (ru)
PL (1) PL216524B1 (ru)
PT (2) PT1419151E (ru)
RS (1) RS53251B (ru)
SI (2) SI1419151T1 (ru)
SK (1) SK902004A3 (ru)
TN (1) TNSN04028A1 (ru)
TR (1) TR201900509T4 (ru)
TW (1) TWI269796B (ru)
UA (1) UA76483C2 (ru)
WO (1) WO2003016305A1 (ru)
ZA (1) ZA200400706B (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016305A1 (en) 2001-08-15 2003-02-27 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
PT1670785E (pt) * 2003-10-02 2010-09-16 Pharmacia & Upjohn Co Llc Sais e polimorfos de um composto de indolinona substituída com pirrole
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
MX2007000892A (es) * 2004-07-22 2007-05-23 Lilly Co Eli Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato.
WO2006120557A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
CN101287724B (zh) 2005-09-19 2013-11-06 硕腾P有限责任公司 经吡咯取代的2-吲哚酮的固态盐形式
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2699305A1 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CN101939314B (zh) * 2007-12-12 2014-04-02 麦迪凯姆股份公司 3-吡咯取代的2-吲哚酮的多晶型物
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
CN101983195A (zh) * 2008-02-21 2011-03-02 基因里克斯(英国)有限公司 新型多晶型物及其制备方法
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
WO2009124037A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
CA2720943A1 (en) 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US8829039B2 (en) 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
EP2313371B1 (en) * 2008-06-13 2012-08-15 Medichem, S.A. Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
US20110257237A1 (en) * 2008-07-10 2011-10-20 Generics [Uk] Limited Process for the preparation of crystalline forms of sunitinib malate
CN102164913A (zh) * 2008-07-24 2011-08-24 麦迪凯姆股份公司 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
EP2373642A2 (en) * 2008-07-24 2011-10-12 Teva Pharmaceutical Industries Ltd Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs
CN102197034A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的新型多晶型物及其制备方法
CA2734965A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
EP2350056A1 (en) * 2008-10-10 2011-08-03 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2373643A4 (en) * 2009-01-02 2013-08-07 Hetero Research Foundation NEW SUNITINIB MALATE POLYMORPHS
WO2010083414A1 (en) 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
WO2011058521A2 (en) * 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011061613A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
EP2528913A1 (en) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
US20130123511A1 (en) 2010-03-04 2013-05-16 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
US20160185760A1 (en) 2010-03-18 2016-06-30 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
EP2828251B1 (en) 2012-03-23 2018-10-31 Laurus Labs Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CA2838585A1 (en) * 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
CA2838587A1 (en) * 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
SG11201602625YA (en) 2013-11-01 2016-05-30 Pfizer Vectors for expression of prostate-associated antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
US20220192989A1 (en) * 2019-04-18 2022-06-23 Meter Health, Inc. Methods and compositions for treating respiratory arrhythmias
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0592438T5 (da) 1990-10-15 1999-12-06 Pfizer Inc. Indolderivater
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
SK279211B6 (sk) 1992-06-05 1998-08-05 Merck Sharp & Dohme Limited Sulfátová soľ substituovaného triazolu, spôsob jej
EP0690864B1 (en) 1993-03-12 2001-06-13 PHARMACIA & UPJOHN COMPANY Crystalline ceftiofur free acid
US6329364B1 (en) 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
PL191313B1 (pl) * 1996-08-14 2006-04-28 Searle & Co Postać krystaliczna 4-[5-metylo-3-fenyloizoksazol-4-ilo] benzenosulfonamidu, sposób jej otrzymywania, zawierająca ją kompozycja farmaceutyczna i zastosowania
CN1104378C (zh) 1996-12-25 2003-04-02 日本化药株式会社 顺铂细粉及其制备方法
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
HU229405B1 (en) * 1998-06-19 2013-12-30 Teijin Pharma Ltd Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and processes for the preparation thereof
WO2000035908A1 (en) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
WO2003016305A1 (en) 2001-08-15 2003-02-27 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
CN101983195A (zh) 2008-02-21 2011-03-02 基因里克斯(英国)有限公司 新型多晶型物及其制备方法
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
MY139383A (en) 2009-09-30
TWI269796B (en) 2007-01-01
KR20040030074A (ko) 2004-04-08
BR0211612A (pt) 2004-08-24
CN100364991C (zh) 2008-01-30
HU229206B1 (en) 2013-09-30
EP2332934B1 (en) 2017-03-01
EP3168218A1 (en) 2017-05-17
AU2002324684B2 (en) 2006-10-05
SK902004A3 (sk) 2005-03-04
PL368317A1 (en) 2005-03-21
EA006445B1 (ru) 2005-12-29
ME00414B (me) 2011-10-10
KR100639281B1 (ko) 2006-10-31
DK1419151T3 (da) 2014-03-31
JP4159988B2 (ja) 2008-10-01
DK3168218T3 (en) 2019-01-14
IL160097A0 (en) 2004-06-20
GEP20063777B (en) 2006-03-27
US20070191458A1 (en) 2007-08-16
PT3168218T (pt) 2019-01-11
HRP20040112B1 (en) 2012-03-31
ECSP044975A (es) 2004-03-23
CZ2004196A3 (cs) 2005-01-12
HK1088008A1 (en) 2006-10-27
EP1419151B1 (en) 2014-02-26
CU23713B7 (es) 2011-10-05
ZA200400706B (en) 2005-05-25
AP2004002976A0 (en) 2004-03-31
OA12650A (en) 2006-06-19
NO326508B1 (no) 2008-12-15
CY1121552T1 (el) 2020-05-29
MA27058A1 (fr) 2004-12-20
PT1419151E (pt) 2014-03-27
CN100439360C (zh) 2008-12-03
AR036261A1 (es) 2004-08-25
EP2332934A1 (en) 2011-06-15
CU20040029A7 (es) 2008-03-14
RS53251B (sr) 2014-08-29
NO20041054L (no) 2004-03-12
AP1660A (en) 2006-09-09
HRP20040112A2 (en) 2004-06-30
HUP0700036A2 (en) 2008-10-28
EP1419151A1 (en) 2004-05-19
TNSN04028A1 (fr) 2006-06-01
RS10304A (en) 2007-02-05
TR201900509T4 (tr) 2019-02-21
ES2623094T3 (es) 2017-07-10
SI1419151T1 (sl) 2014-04-30
EA200400183A1 (ru) 2004-08-26
JP2005503386A (ja) 2005-02-03
ES2453164T3 (es) 2014-04-04
WO2003016305A1 (en) 2003-02-27
IS7147A (is) 2004-02-10
NZ531232A (en) 2004-11-26
EP3168218B1 (en) 2018-11-14
UA76483C2 (en) 2006-08-15
CO5550431A2 (es) 2005-08-31
ES2705063T3 (es) 2019-03-21
SI3168218T1 (sl) 2019-05-31
HK1066542A1 (en) 2005-03-24
PL216524B1 (pl) 2014-04-30
BG108553A (bg) 2005-04-30
CN1789264A (zh) 2006-06-21
MXPA04001452A (es) 2004-05-20
US20030069298A1 (en) 2003-04-10
CN1543462A (zh) 2004-11-03
CA2455050A1 (en) 2003-02-27
US7435832B2 (en) 2008-10-14
CA2455050C (en) 2007-02-20

Similar Documents

Publication Publication Date Title
MXPA04001452A (es) Cristales anhidros que incluyen una sal del acido malonico de una 2-indolinona sustituida con 3-prrol, metodos de preparacion y composiciones que los contienen.
IL189358A0 (en) Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide
DE60218703D1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
UA93351C2 (ru) Производные фталазина kak ингибиторы parp
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
WO2010010454A3 (en) Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
GB0425548D0 (en) Radiolabelled ligands
EP1406614A4 (en) CARVEDILOLPOLYMORPH
CY1115143T1 (el) Κρυσταλλοι που περιλαμβανουν μηλικο αλας του ν-[2-(διαιθυλαμινο)αιθυλο]-5-[(5-φθορο-1,2-διϋδρο-2-οξο-3η-ινδολ-3-ιλιδενο)μεθυλο]-2,4-διμεθυλο-1η-πυρρολο-3-καρβοξαμιδιου, διεργασιες παρασκευης αυτων και συνθεσεις αυτων
SG145572A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
TH69655A (th) ผลึกซึ่งประกอบด้วยเกลือของกรดมาลิคของ 3-ไพร์รอล ซับสทิทิวเทด 2-อินโดลิโนน และสารผสมของสารเหล่านี้
TW200740442A (en) Therapeutic agent for hypertension

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title